Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.

NeXT Personal was applied to 24 people with metastatic esophagogastric cancer in the phase 2 KeyLargo study, and every patient was ctDNA-positive at baseline.

Scientific ReportsPubMed 41872254DOI 10.1038/s41598-026-43178-4